BRPI1005349A2 - proteína para imunocastração de mamíferos - Google Patents

proteína para imunocastração de mamíferos

Info

Publication number
BRPI1005349A2
BRPI1005349A2 BRPI1005349A BRPI1005349A BRPI1005349A2 BR PI1005349 A2 BRPI1005349 A2 BR PI1005349A2 BR PI1005349 A BRPI1005349 A BR PI1005349A BR PI1005349 A BRPI1005349 A BR PI1005349A BR PI1005349 A2 BRPI1005349 A2 BR PI1005349A2
Authority
BR
Brazil
Prior art keywords
fusion protein
immunocastration
mammalian
protein
vaccine
Prior art date
Application number
BRPI1005349A
Other languages
English (en)
Inventor
Enrique Saenz Iturriaga Leonardo
Original Assignee
Univ Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chile filed Critical Univ Chile
Publication of BRPI1005349A2 publication Critical patent/BRPI1005349A2/pt
Publication of BRPI1005349B1 publication Critical patent/BRPI1005349B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0006Contraceptive vaccins; Vaccines against sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

proteína de fusão para imunocastração, sequências de dna, vacina veterinária e uso da mesma, processo para produção de uma vacina veterinária e processo para preparar uma proteína de fusão a presente invenção refere-se a uma proteína de fusão que incorpora o hormônio liberador de gonadotrofinas (gnrh) para a imunocastração de mamíferos, sequências de dna que codificam a referida proteína de fusão, vacina que compreende a referida proteína de fusão, e processo para preparar a proteína de fusão. a proteína de fusão incorpora a sequência aminoacídica do hormônio gnrh fundida a uma de acordo com a seq id no: 14, não derivada de patógeno, com capacidade imunogênica e que contém sítios de 0-glicosilação.
BRPI1005349-2A 2009-04-15 2010-04-14 Proteína de fusão para imunocastração, sequências de dna, vacina veterinária e uso da mesma, processo para produção de uma vacina veterinária e processo para preparar uma proteína de fusão BRPI1005349B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CL900-2009 2009-04-15
CL2009000900A CL2009000900A1 (es) 2009-04-15 2009-04-15 Proteina de fusion que comprende la hormona liberadora de gonadotrofinas fusionada a una secuencia con capacidad inmunogenica con sitios de o-glicosilacion; secuencia de adn que la codifica; procedimiento de produccion; vacuna que las comprende; y su uso para inmunocastracion de mamiferos.
PCT/CL2010/000014 WO2010118547A1 (es) 2009-04-15 2010-04-14 Proteína de inmunocastración de mamíferos

Publications (2)

Publication Number Publication Date
BRPI1005349A2 true BRPI1005349A2 (pt) 2019-07-02
BRPI1005349B1 BRPI1005349B1 (pt) 2021-05-25

Family

ID=42635208

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1005349-2A BRPI1005349B1 (pt) 2009-04-15 2010-04-14 Proteína de fusão para imunocastração, sequências de dna, vacina veterinária e uso da mesma, processo para produção de uma vacina veterinária e processo para preparar uma proteína de fusão

Country Status (9)

Country Link
US (1) US8940693B2 (pt)
EP (1) EP2431052B1 (pt)
AR (1) AR075953A1 (pt)
BR (1) BRPI1005349B1 (pt)
CL (1) CL2009000900A1 (pt)
DK (1) DK2431052T5 (pt)
ES (1) ES2467702T3 (pt)
PL (1) PL2431052T3 (pt)
WO (1) WO2010118547A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102477054B1 (ko) * 2020-03-24 2022-12-14 주식회사 바이오앱 웅취 제거용 재조합 단백질 및 이를 포함하는 백신 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975420A (en) 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
US6761890B1 (en) 1995-06-07 2004-07-13 Pepscan Systems B.V. Peptide, immunogenic composition and vaccine or medical preparation, a method to immunize animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
US6013770A (en) 1997-07-21 2000-01-11 Washington State University Chimeric contraceptive vaccines
US20060121051A1 (en) * 1998-02-19 2006-06-08 Kenten John H Heat shock fusion-based vaccine system
EP1303533A2 (en) 2000-05-05 2003-04-23 Aphton Corporation Chimeric peptide immunogens, their preparation and use
WO2003089590A2 (en) 2002-04-16 2003-10-30 Vaxin, Inc. TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
US20040202673A1 (en) * 2003-04-08 2004-10-14 Jen-Pin Huang Constructs of branched synthetic peptide immunogens with artificial T helper cell epitopes coupled to B cell epitopes
WO2007137586A2 (en) * 2006-05-31 2007-12-06 Pharmexa A/S Random insertion of peptides

Also Published As

Publication number Publication date
DK2431052T5 (da) 2014-07-07
CL2009000900A1 (es) 2009-08-14
US20120093846A1 (en) 2012-04-19
ES2467702T3 (es) 2014-06-12
PL2431052T3 (pl) 2014-09-30
EP2431052A1 (en) 2012-03-21
WO2010118547A1 (es) 2010-10-21
EP2431052B1 (en) 2014-04-02
AR075953A1 (es) 2011-05-11
DK2431052T3 (da) 2014-06-30
BRPI1005349B1 (pt) 2021-05-25
US8940693B2 (en) 2015-01-27

Similar Documents

Publication Publication Date Title
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
ECSP12011577A (es) Produccion recombinante de péptidos
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
HK1134507A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
CL2012000886A1 (es) Polipeptido que comprende dos secuencias aminoacidas que permiten la union especifica al receptor para productos finales de glicosilacion avanzada (rpfga); uno o mas acidos nucleicos que codifican el polipeptido; celula; composicion; metodo para diagnosticar enfermedad o trastorno con rpfga.
BR112012027893A2 (pt) peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada.
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
BRPI0513426A (pt) processo de preparação de amino ácidos úteis na preparação de moduladores de receptores de peptìdeos
UA98620C2 (uk) Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
PE20201067A1 (es) Anticuerpos anti-csf 1r
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
BRPI0512935A (pt) processo para a preparação de aminoácido úteis na preparação de moduladores receptores de peptìdeo
AR071696A1 (es) Vacuna contra leishmania usando un inmunogeno salival de la mosca de la arena. metodos.
BRPI1005349A2 (pt) proteína para imunocastração de mamíferos
AR080621A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria
BR112012030084A2 (pt) peptídeos que se ligam a receptores do fator de crescimento semelhante à insulina tipo 1
MX2010005816A (es) Epítopos de péptido de stat3.
AR071635A1 (es) Variantes de crig (receptor asociado a macrofagos) que tienen afinidad de union aumentada a c3b, con union selectiva sobre c3 (ambas proteinas del complemento).
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF